CANADIAN CANCER TRIALS GROUP

TESTES AND KIDNEY

GU DISEASE ORIENTED GROUP MEETING AGENDA

CHELSEA HOTEL, TORONTO, ON

ROOM: JAMES

SATURDAY APRIL 29TH, 2017, 7:00 AM – 8:00 AM

CO-CHAIRS: A. KAPOOR, C. KOLLMANNSSBERGER, P. CHUNG & D.HENG

SENIOR INVESTIGATOR: FRANCISCO VERA-BADILLO

STUDY COORDINATOR: ALEXANDER MONTENEGRO & P. STOS

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (renal and testicular cancer) in Canada.
- To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.
- To update, review, and discuss recent results of clinical studies conducted by the Canadian Cancer Trials Group and/or by national/international collaborators.
- To provide mentoring opportunities for investigators new to clinical trial research.
- To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.

7:00 am  Welcome

CCTG InterGroup OPEN TRIALS

7:05 am  REC.3/PAPMET A randomized, phase II efficacy assessment of multiple MET kinase inhibitors cabozantinib, crizotinib and savolitinib versus sunitinib in metastatic papillary renal carcinoma. D. Heng

TRIAL PROPOSAL UPDATE

7:15 am  InPACT, the international trial for multimodality management of node positive penile cancer J. Cook

7:35 am  EA8143 (PROSPER): Phase III Perioperative nivolumab in M0 RCC A. Kapoor/ D. Heng

7:50 am  SBRT for RCC: Canadian multi-centre phase II study comparing a 3- versus a 5- fraction SBRT protocol. W. Chu

8:00 am  Meeting Adjourned